Evaxion picks gonorrhea as second target for vaccine candidate

Encouraging pre-clinical results for Evaxion’s EVX-BV2 candidate have led the firm to add a second target indication, gonorrhea.

Lars Staal Wegner, CEO of Evaxion Biotech | Photo: Evaxion Biotech / PR

by andreas lønstrup, translated by catherine brett

Published: 01.07.22 at 10:52

Evaxion Biotech has announced that the firm has chosen sexually transmitted disease gonorrhea as the second target of its EVX-B2 vaccine candidate.

The biotech firm develops vaccines and immunotherapies based on artificial intelligence.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

ALK to exit Turkish market: "It's bad business if all we get is peanuts"

ALK's Turkish workforce will have look for employment elsewhere | Foto: ALK / PR

A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.

Genmab postpones crucial cancer candidate decision following Abbvie exit

For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.

Genmab says new arbitration builds on a straightforward question

”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.